Project description
Innovative platform to address MASLD burden
The disease burden and comorbidities associated with Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) pose significant challenges to public health systems. Therefore, there is an urgent need to transform healthcare practices related to MASLD and alleviate the disease burden for patients. The EU-funded GRIPonMASH project aims to address this need by developing a sustainable and scalable platform for the early detection of at-risk patients developing or already diagnosed with MASLD at the primary care level. This platform, implemented across 12 European Centres of Excellence, will facilitate improved patient stratification through AI-based decision support tools utilising both existing and novel biomarkers. Additionally, it will offer personalised lifestyle advice by examining evidence-based lifestyle factors and the impact of nutritional recommendations.
Objective
GRIP on MASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Together with seven medical technology, pharmaceutical and biotechnology companies, we will devise a sustainable and scalable GRIP on MASH Platform that will enable access to at-risk patients developing or having MASLD through the early detection of this condition at the primary care level. This Platform will allow A) the early detection of patients with MASLD: distributed in 12 European Centers of Excellence (CoEs), 10,000 patients at high risk of MASLD - defined as patients with type-2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension - will be screened and characterized; B) better patients’ stratification: the Platform will comprise artificial intelligence-based decision support tools that will make use of existing and novel biomarkers/biomarker combinations. Their predictive accuracy will be tested at the primary care level; there we will perform multi-OMICs analysis (proteomics, lipidomics, metabolomics, genomics, metagenomics and fluxomics) in fasted blood samples and we will explore imaging biomarkers/organ-on-a-chip to find future non-invasive diagnostic alternatives for the current standard (liver biopsies); and C) personalized lifestyle advice, by exploring evidence-based lifestyle features and the effect of nutritional recommendations: among the cohorts at the CoEs, we will use validated questionnaires to assess physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress. Integrating patients’ perspectives with the participation of two patient organizations, the trustworthiness and sustainability of our GRIP on MASH Platform will be assessed by investigating potential economic, ethical and regulatory barriers to its future adoption. GRIP on MASH will change healthcare practice in MASLD and reduce the disease burden for patients.
Fields of science
- medical and health scienceshealth sciencespublic health
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinehepatology
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
- medical and health scienceshealth sciencesnutritionobesity
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
3584 CX Utrecht
Netherlands
See on map
Participants (28)
75014 Paris
See on map
2342 DH Oegstgeest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2730 Herlev
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
3584 BH Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
2311 EZ Leiden
See on map
1081 HV Amsterdam
See on map
41071 Sevilla
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
41013 Sevilla
See on map
00185 Roma
See on map
2333 ZA Leiden
See on map
1050 Bruxelles / Brussel
See on map
2650 Edegem
See on map
20123 Milano
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
00168 Roma
See on map
011826 Bucuresti
See on map
1050 Bruxelles / Brussel
See on map
176 71 ATHINA
See on map
12808 Praha 2
See on map
55131 Mainz
See on map
2880 Bagsvaerd
See on map
3703 CD Zeist
See on map
6200 MD Maastricht
See on map
754 50 Uppsala
See on map
2313 NV Leiden
See on map
41251 GOTEBORG
See on map
SW6 7UR LONDON
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1649-028 Lisbon
See on map
75013 Paris
See on map